Desmopressin for treating nocturia in patients with multiple sclerosis: A systematic review: A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
- 17 January 2019
- journal article
- review article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (2) , 563-571
Abstract
Aims To systematically assess all available evidence on efficacy and safety of desmopressin for treating nocturia in patients with multiple sclerosis (MS). Methods This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. Studies were identified by electronic search of Cochrane register, Embase, Medline, Scopus (last search March 3, 2018) and by screening of reference lists and reviews. Results After screening of 7015 abstracts, 8 prospective, and 1 retrospective studies were included enrolling a total of 178 patients. The mean patient age ranged between 43 and 51 years. A significant decrease in the number of micturitions per night was reported in 5 studies. An increase in the maximum hours of uninterrupted sleep was only found in two studies. A significant reduction of the volume of nocturnal incontinence was described in one study. The patient satisfaction rates ranged from 56% to 82%. The rate of adverse events was between 0% and 57.9%. The rate of hyponatremia ranged from 0% to 23.5% and other commonly reported adverse events were headache, nausea, fluid retention, rhinitis/epistaxis, malaise, and swollen ankles. Risk of bias and confounding was relevant in all studies. Conclusions Preliminary data suggest that desmopressin might be effective for treating nocturia in patients with MS. However, adverse events are relatively common, the overall quality of evidence is low and the number of studied patients is very limited. Further studies with newer formulations of desmopressin are highly warranted.Keywords
Funding Information
- Swiss Continence Foundation
This publication has 29 references indexed in Scilit:
- Nocturia as a manifestation of systemic diseaseBJU International, 2011
- Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosisMultiple Sclerosis Journal, 2007
- Long term use of Desmopressin for urinary symptoms in multiple sderosisMultiple Sclerosis Journal, 1999
- Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosisActa Neurologica Scandinavica, 1996
- An open, in‐patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturiaBritish Journal of Urology, 1995
- Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosisBritish Journal of Urology, 1994
- Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Desmopressin: A new Principle for Symptomatic Treatment of Urgency and Incontinence in Patients with Multiple SclerosisScandinavian Journal of Urology and Nephrology, 1990
- The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1983